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299 Chiari type I malformation in two adult patients with cystic
ﬁbrosis
D. Narasimhaiah1, C. Etherington1, G. Fitch1, P. Whitaker1, D. Peckham1. 1St
James’s University Hospital, Regional Adult Cystic Fibrosis Unit, Leeds, United
Kingdom
Objectives: The Cystic Fibrosis (CF) gene is associated with abnormal production
and function of the cystic ﬁbrosis transmembrane conductance regulator (CFTR).
Despite the widespread expression of CFTR in the brain, neurological complications
and malformations of the central nervous system (CNS) are rare. We report two
cases of Chiari malformations in adults with CF.
Methods: Case records were reviewed. Diagnoses were conﬁrmed by brain MRI
scan and neurological assessment.
Results: Since 2006, 440 patients (17 years) have been followed up in the
adult unit. Two patients were diagnosed as having Chiari Type 1 malformation.
The ﬁrst case involved a 26 years old female who presented with secondary
amenorrhea due to hypogonadotrophic hypogonadism. Brain MRI demonstrated
Chiari type I malformation with hydrocephalus requiring a third ventriculostomy
and decompression of foramen magnum. The second patient was a 23 year old male
who presented with type II respiratory failure and persistent headache which failed
to respond to non invasive ventilation. Brain MRI conﬁrmed Chiari I malformation
without evidence of hydrocephalus.
Conclusion: Chiari type I malformation is characterized by herniation of the
cerebellar tonsils through the foramen magnum and can be either asymptomatic
or present with a wide spectrum of neurological symptoms. Although rare (1:1000
births), Chiari type I malformation may be more frequent in patients with CF [1].
The diagnosis should be considering in patients presenting with neurological
symptoms.
Reference(s)
[1] Needleman JP et al. Chiari type I malformation in children and adolescents with
cystic ﬁbrosis. Pediatr Pulmonol 2000, 30: 490–492.
300 Pseudomonas aeruginosa colonization in a CF child’s upper and
lower airways: a father’s meticulous approach to successful
eradication
A. Gerber1, T. Ebener1, M. Lorenz1, J. Hentschel1, W. Pﬁster2, J.F. Beck1,
J.G. Mainz1. 1Jena University Hospital, CF-Centre, Jena, Germany; 2Jena
University Hospital, Institute of Medical Microbiology, Jena, Germany
First Pseudomonas aeruginosa (PSA) colonization of the presently 8-year-old
male patient with CF was diagnosed by a routine deep throat swab. Subsequently
both, the upper and lower airways (UAW/LAW) were sampled monthly by throat
swabs/sputum collection, and nasal lavage, according to the Jena CF-centers’
standard for intermittent colonization. The boy’s father meticulously documented
all therapies and culture results.
Initial attempts to eradicate PSA following current German guidelines, with oral
ciproﬂoxacin, inhaled colistin and tobramycin, as well as three cycles of IV
ceftazidime and tobramycin failed. After the ﬁrst positive nasal sample, vibrating
nasal inhalation of nebulized colistin (Pari Sinus) was added to the regimen. After 9
positive cultures of PSA from the LAW and 3 from the UAW, we changed to an off-
label regimen consisting of inhaled aztreonam alternating monthly with tobramycin
(given simultaneously for UAW and LAW, and IV antibiotics every 3 months, and
oral azithromycin).
Our patient has now been free of PSA for one year, as documented by monthly
negative cultures. This case demonstrates that routine sampling of lower and upper
airways may reveal early nasal colonization, which if unrecognized, would have
precluded successful LAW eradication. Monthly sampling detected intermittent
colonization and conﬁrmed complete clearance of PSA. Both would not have been
achieved following international standards for CF care, which only recommend
LAW sampling, 2−4 times/year. Bronchial antibiotic inhalation alone would likely
have missed treating the UAW. The whole process was closely monitored by the
boy’s father. We want to thank him for his commitment.
301 Aspergillus nodi in cystic ﬁbrosis (CF) patients: a rare entity.
Report of two pediatric cases
P. Schelstraete1, S. Van Daele1, F. Haerynck1, F. De Baets1. 1Ghent University
Hospital, Cystic Fibrosis Reference Center, Ghent, Belgium
Introduction: Aspergillus nodi are rarely reported in CF, mostly in adult patients
with CF-related diabetes and severe pulmonary damage (FEV1 <25%) and/or under
immunosuppresive treatment. This complication is rarely seen in children. We report
two CF children with aspergillus nodus.
Cases: Patient 1 presented at the age of 13 y with dyspnoe, thoracal pain and
cough without fever. Chest X-ray and HRCT revealed a round pneumonia in the
right upper lobe. A. fumigatus was cultured of bronchoalveolar lavage (BAL) ﬂuid,
BAL galactomannan was positive. A complete cure was obtained after a 6 month
treatment of orally administrated antifungals (voriconazole initially, switched to
itraconazole because of side effects).
Patient 2 was seen on the outpatient department at the age of 9 y because
of pain during inspiration and a mild cough without fever. Lung HRCT scan
revealed a nodular lesion in the right upper lobe. BAL ﬂuid culture was positive
for A. fumigatus, BAL galactomannan was positive. Treatment consisted of oral
voriconazole during 6 months, after which complete healment was obtained.
Conclusion: Although invasive infections by A. fumigatus are preferentially but
rarely seen in CF adults with underlying conditions, aspergillus nodi should also
be considered as a rare complication in CF children without predisposing factors.
302 Comparison of airway clearance techniques (ACT) in the cystic
ﬁbrosis (CF) population: a single case study report
E. Forster1, E. Swingwood1, B. Nicholas1, K. Bateman1. 1UHBristol NHS
Foundation Trust, Bristol Adult Cystic Fibrosis Centre, Bristol, United Kingdom
Objective: Airway clearance techniques (ACT) are an integral component of CF
care, although the most effective method is debated. Non-invasive ventilation (NIV)
and Intermittent Positive Pressure Breathing (IPPB) are commonly used. Mechanical
Insufﬂation:Exsufﬂation (MI:E) may provide a useful alternative. To compare ACT
performance we reviewed ﬂow and pressure breath proﬁles and regional lung
ventilation (RLV) via Electrical Impedance Tomography (EIT).
Method: IPPB (Pressure 28−30 cmH2O), NIV (28/6) and MI:E (Insufﬂation +28
cmH2O:Exsufﬂation −38 cmH2O) were used in 3 separate ACT sessions over a
2 week period in 1 CF patient. Constant monitoring of breath proﬁles and RLV via
EIT occurred. A 10-point visual analogue scale (VAS) for ease of sputum clearance
was recorded pre and post treatment.
Results: RLV increased during all ACT from baseline and was signiﬁcant for MI:E
and NIV (p< 0.05). NIV breath proﬁles suggested limitation of expiratory ﬂow
in comparison to the exsufﬂation breath of MI:E and IPPB breaths, where an
expiratory ﬂow bias was apparent. Expiratory ﬂow bias is essential for effective
ACT, preventing embedding of mucus. MI:E was reported as most effective ACT
by the patient, with VAS for ease of clearance reducing from 6 to 3.
Conclusion: Lung recruitment occurred with all ACT. NIV may limit expiratory
ﬂow and sputum clearance. IPPB and MI:E may facilitate sputum clearance due
to expiratory ﬂow bias. Patient-reported VAS for ease of sputum clearance favored
MI:E. This is a single case study report; further research may be of beneﬁt to
further investigate the potential use of MI:E in CF.
